NO20082684L - F-, G-, H-, I- og K-krystallformer av imatinibmesylat - Google Patents
F-, G-, H-, I- og K-krystallformer av imatinibmesylatInfo
- Publication number
- NO20082684L NO20082684L NO20082684A NO20082684A NO20082684L NO 20082684 L NO20082684 L NO 20082684L NO 20082684 A NO20082684 A NO 20082684A NO 20082684 A NO20082684 A NO 20082684A NO 20082684 L NO20082684 L NO 20082684L
- Authority
- NO
- Norway
- Prior art keywords
- crystal form
- crystal forms
- imatinib mesylate
- warm
- preparation
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 7
- 229960003685 imatinib mesylate Drugs 0.000 title 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 title 1
- -1 4-methylpiperazin-1-ylmethyl Chemical group 0.000 abstract 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229940098779 methanesulfonic acid Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0524061A GB0524061D0 (en) | 2005-11-25 | 2005-11-25 | Organic compounds |
| GB0524062A GB0524062D0 (en) | 2005-11-25 | 2005-11-25 | Organic compounds |
| US74001805P | 2005-11-28 | 2005-11-28 | |
| US74001605P | 2005-11-28 | 2005-11-28 | |
| US74001705P | 2005-11-28 | 2005-11-28 | |
| PCT/EP2006/011240 WO2007059963A1 (en) | 2005-11-25 | 2006-11-23 | F,g,h,i and k crystal forms of imatinib mesylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082684L true NO20082684L (no) | 2008-08-15 |
Family
ID=37847165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082684A NO20082684L (no) | 2005-11-25 | 2008-06-16 | F-, G-, H-, I- og K-krystallformer av imatinibmesylat |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US7893076B2 (enExample) |
| EP (3) | EP2578580A1 (enExample) |
| JP (2) | JP5844508B2 (enExample) |
| KR (4) | KR20130141712A (enExample) |
| CN (1) | CN102351842B (enExample) |
| AU (2) | AU2006316823A1 (enExample) |
| BR (1) | BRPI0618993A2 (enExample) |
| CA (3) | CA2824301C (enExample) |
| EC (1) | ECSP088473A (enExample) |
| MY (1) | MY146403A (enExample) |
| NO (1) | NO20082684L (enExample) |
| UY (1) | UY29964A1 (enExample) |
| WO (1) | WO2007059963A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144177A (en) * | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| AU2006316823A1 (en) * | 2005-11-25 | 2007-05-31 | Novartis Ag | F,G,H,I and K crystal forms of imatinib mesylate |
| MX2010003200A (es) * | 2007-09-25 | 2010-04-30 | Teva Pharma | Composiciones de imatibnib estables. |
| RU2365587C1 (ru) * | 2008-02-22 | 2009-08-27 | Закрытое Акционерное Общество "Фарм-Синтез" | Рентгеноаморфная безводная модификация 4-[(4-метил-1-пиперазинил)метил]-n-[4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]-амино]-фенил]бензамида метансульфоната и способ ее получения |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| PL389357A1 (pl) | 2009-10-22 | 2011-04-26 | Tomasz Koźluk | Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania |
| EP2536707A1 (en) | 2010-02-15 | 2012-12-26 | Reliance Life Sciences Pvt., Ltd. | Process for the preparation of alpha form of imatinib mesylate |
| PL390611A1 (pl) | 2010-03-04 | 2011-09-12 | Tomasz Koźluk | Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu |
| WO2012090221A1 (en) | 2010-12-29 | 2012-07-05 | Cadila Healthcare Limited | Novel salts of imatinib |
| EP2604596A1 (en) * | 2011-12-16 | 2013-06-19 | Deva Holding Anonim Sirketi | Polymorphs of imatinib |
| CA2877030A1 (en) | 2012-06-22 | 2013-12-27 | Basf Se | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers |
| KR101242955B1 (ko) * | 2012-06-25 | 2013-03-12 | 제일약품주식회사 | 이마티닙 메실레이트 결정형 α의 제조 방법 |
| ES2683361T3 (es) | 2013-05-14 | 2018-09-26 | Hetero Research Foundation | Composiciones de Imatinib |
| WO2015081175A1 (en) * | 2013-11-26 | 2015-06-04 | Children's Medical Center Corporation | Expandable stent valve |
| PL3539138T3 (pl) | 2016-11-11 | 2021-12-13 | Curium Us Llc | Sposoby generowania germanu-68 ze zmniejszoną ilością części lotnych |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (enExample) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US20060073185A1 (en) | 2002-12-13 | 2006-04-06 | Bausch & Lomb Incorporated | Method and composition for contact lenses |
| WO2004106326A1 (en) * | 2003-06-02 | 2004-12-09 | Hetero Drugs Limited | Novel polymorphs of imatinib mesylate |
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| PL1720853T3 (pl) * | 2004-02-11 | 2016-06-30 | Natco Pharma Ltd | Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania |
| UA84462C2 (ru) | 2004-04-02 | 2008-10-27 | Институт Фармацевтични | Полиморфные модификации кислотно-аддитивных солей иматиниба с метансульфоновой кислотой |
| KR101246863B1 (ko) | 2004-06-04 | 2013-03-25 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 간 장애 및 바이러스성 감염의 치료를 위한 이매티닙의용도 |
| TR200701870T1 (tr) | 2004-09-02 | 2007-05-21 | Cipla Limited | İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. |
| WO2006048890A1 (en) | 2004-11-04 | 2006-05-11 | Sun Pharmaceutical Industries Limited | Imatinib mesylate crystal form and process for preparation thereof |
| WO2006054314A1 (en) | 2004-11-17 | 2006-05-26 | Natco Pharma Limited | Polymorphic forms of imatinib mesylate |
| US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
| GB0511066D0 (en) | 2005-05-31 | 2005-07-06 | Novartis Ag | Organic compounds |
| JP2009506014A (ja) | 2005-08-26 | 2009-02-12 | ノバルティス アクチエンゲゼルシャフト | イマチニブメシレートのデルタおよびイプシロン結晶形 |
| AU2006316823A1 (en) * | 2005-11-25 | 2007-05-31 | Novartis Ag | F,G,H,I and K crystal forms of imatinib mesylate |
-
2006
- 2006-11-23 AU AU2006316823A patent/AU2006316823A1/en not_active Abandoned
- 2006-11-23 EP EP12177131.5A patent/EP2578580A1/en not_active Withdrawn
- 2006-11-23 CA CA2824301A patent/CA2824301C/en not_active Expired - Fee Related
- 2006-11-23 KR KR1020137031543A patent/KR20130141712A/ko not_active Ceased
- 2006-11-23 CN CN201110232553.6A patent/CN102351842B/zh not_active Expired - Fee Related
- 2006-11-23 EP EP06818763A patent/EP1960380A1/en not_active Withdrawn
- 2006-11-23 EP EP12177119A patent/EP2546248A1/en not_active Withdrawn
- 2006-11-23 CA CA2824307A patent/CA2824307C/en not_active Expired - Fee Related
- 2006-11-23 KR KR1020137031545A patent/KR20130137721A/ko not_active Ceased
- 2006-11-23 KR KR1020087012363A patent/KR20080078804A/ko not_active Ceased
- 2006-11-23 KR KR1020137031544A patent/KR20130140909A/ko not_active Ceased
- 2006-11-23 BR BRPI0618993-8A patent/BRPI0618993A2/pt not_active IP Right Cessation
- 2006-11-23 CA CA2628330A patent/CA2628330C/en not_active Expired - Fee Related
- 2006-11-23 MY MYPI20081624A patent/MY146403A/en unknown
- 2006-11-23 WO PCT/EP2006/011240 patent/WO2007059963A1/en not_active Ceased
- 2006-11-23 UY UY29964A patent/UY29964A1/es not_active Application Discontinuation
- 2006-11-23 US US12/094,629 patent/US7893076B2/en not_active Expired - Fee Related
- 2006-11-23 JP JP2008541641A patent/JP5844508B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-20 EC EC2008008473A patent/ECSP088473A/es unknown
- 2008-06-16 NO NO20082684A patent/NO20082684L/no not_active Application Discontinuation
-
2011
- 2011-01-14 US US13/006,505 patent/US8198289B2/en not_active Expired - Fee Related
- 2011-03-22 AU AU2011201286A patent/AU2011201286A1/en not_active Ceased
- 2011-07-15 US US13/183,572 patent/US8592440B2/en not_active Expired - Fee Related
- 2011-07-15 US US13/183,557 patent/US8507515B2/en not_active Expired - Fee Related
- 2011-07-15 US US13/183,600 patent/US8846706B2/en not_active Expired - Fee Related
-
2012
- 2012-05-15 US US13/472,000 patent/US8633213B2/en not_active Expired - Fee Related
-
2014
- 2014-01-16 JP JP2014005741A patent/JP2014074067A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
| NO20064347L (no) | Substituerte 1,2,3,4-tetrahydroisokinolinderivater | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| NO20082673L (no) | Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens | |
| MX2009013272A (es) | Formas amorfas estabilzadas de mesilato de imatinib. | |
| NO20066055L (no) | Pyridinderivater | |
| NO20081211L (no) | Xantinderivater som selektive HM74A agonister | |
| NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
| NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
| NO20050828L (no) | lndol-3-svovelderivater | |
| NO20076635L (no) | Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter | |
| NO20080675L (no) | P38-Map kinaseinhibitorer og metoder for deres anvendelse | |
| NO20051726L (no) | Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser | |
| NO20071197L (no) | Sulfonamidderivater, deres fremstilling og deres terapeutiske anvendelse | |
| NO20051165L (no) | Benzotiazolderivater som har -adrenoerseptorantagonist aktivitet | |
| NO20064015L (no) | Kondenserte derivater av pyrazol | |
| NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
| NO20075992L (no) | Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav | |
| NO20073140L (no) | Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser | |
| NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
| NO20063748L (no) | Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer | |
| UA95199C2 (en) | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | |
| NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
| NO20082026L (no) | Deazapuriner som er nyttige som inhibitorer for Janus-kinaser | |
| NO20051100L (no) | Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |